| Literature DB >> 28465379 |
Nicholas A Zwang1, Joseph R Leventhal2.
Abstract
Renal transplantation is the renal replacement modality of choice for suitable candidates with advanced CKD or ESRD. Prevention of rejection, however, requires treatment with nonspecific pharmacologic immunosuppressants that carry both systemic and nephrologic toxicities. Use of a patient's own suppressive regulatory T cells (Tregs) is an attractive biologic approach to reduce this burden. Here, we review the immunologic underpinnings of Treg therapy and technical challenges to developing successful cell therapy. These issues include the selection of appropriate Treg subsets, ex vivo Treg expansion approaches, how many Tregs to administer and when, and how to care for patients after Treg administration.Entities:
Keywords: Cell transfer; immunology; kidney transplantation; tolerance
Mesh:
Year: 2017 PMID: 28465379 PMCID: PMC5491296 DOI: 10.1681/ASN.2016111206
Source DB: PubMed Journal: J Am Soc Nephrol ISSN: 1046-6673 Impact factor: 10.121